Avraham Beigelman1, Bradley E Chipps, Leonard B Bacharier. 1. Division of Pediatric Allergy, Immunology, and Pulmonary Medicine, Washington University School of Medicine and St. Louis Children's Hospital, St. Louis, Missouri, USA.
Abstract
BACKGROUND: Corticosteroids, delivered systemically and by inhalation, are widely used for the treatment of multiple acute respiratory illnesses in children. However, the level of evidence to support the utility of this therapy varies between these different acute respiratory illnesses. OBJECTIVE: To summarize the evidence regarding the utility of corticosteroids in the management of common acute pediatric respiratory conditions and to highlights the controversies regarding their use. METHODS: Literature search of manuscripts describing the evidence regarding the efficacy of corticosteroids (systemic and inhaled) in the management of: acute asthma exacerbation among school age children, acute episodic wheeze among preschool children, viral croup, and acute viral bronchiolitis. RESULTS: Current evidence indicates that systemic corticosteroids provide benefits for the treatment of acute asthma exacerbations in school age children, mainly in the acute care setting. In addition, high dose inhaled corticosteroid therapy administered in the Emergency Department appears to have comparable effect for the prevention of asthma-related hospital admission as systemic corticosteroids in this age group. In contrast, most available studies have not shown benefit for systemic corticosteroids during acute wheezing episodes in preschool children. Systemic corticosteroids decrease symptoms and the rate of hospital admissions in patients with severe croup; however, corticosteroids have no role in the treatment of acute bronchiolitis and their use in this condition should be discouraged. CONCLUSION: Corticosteroids treatment response varies between the acute respiratory illnesses presented in this review. Future research should aim to fill the current gaps-of-knowledge regarding the utility this intervention such as the identification of specific wheezing phenotypes among preschool children which might benefit from systemic corticosteroids as a treatment for acute viral wheeze.
BACKGROUND: Corticosteroids, delivered systemically and by inhalation, are widely used for the treatment of multiple acute respiratory illnesses in children. However, the level of evidence to support the utility of this therapy varies between these different acute respiratory illnesses. OBJECTIVE: To summarize the evidence regarding the utility of corticosteroids in the management of common acute pediatric respiratory conditions and to highlights the controversies regarding their use. METHODS: Literature search of manuscripts describing the evidence regarding the efficacy of corticosteroids (systemic and inhaled) in the management of: acute asthma exacerbation among school age children, acute episodic wheeze among preschool children, viral croup, and acute viral bronchiolitis. RESULTS: Current evidence indicates that systemic corticosteroids provide benefits for the treatment of acute asthma exacerbations in school age children, mainly in the acute care setting. In addition, high dose inhaled corticosteroid therapy administered in the Emergency Department appears to have comparable effect for the prevention of asthma-related hospital admission as systemic corticosteroids in this age group. In contrast, most available studies have not shown benefit for systemic corticosteroids during acute wheezing episodes in preschool children. Systemic corticosteroids decrease symptoms and the rate of hospital admissions in patients with severe croup; however, corticosteroids have no role in the treatment of acute bronchiolitis and their use in this condition should be discouraged. CONCLUSION: Corticosteroids treatment response varies between the acute respiratory illnesses presented in this review. Future research should aim to fill the current gaps-of-knowledge regarding the utility this intervention such as the identification of specific wheezing phenotypes among preschool children which might benefit from systemic corticosteroids as a treatment for acute viral wheeze.
Authors: S Schuh; J Reisman; M Alshehri; A Dupuis; M Corey; R Arseneault; G Alothman; O Tennis; G Canny Journal: N Engl J Med Date: 2000-09-07 Impact factor: 91.245
Authors: Geórgia K M Milani; Nelson A Rosário Filho; Carlos A Riedi; Bonald C Figueiredo Journal: J Pediatr (Rio J) Date: 2004 Mar-Apr Impact factor: 2.197
Authors: Péter Csonka; Minna Kaila; Pekka Laippala; Marja Iso-Mustajärvi; Timo Vesikari; Per Ashorn Journal: J Pediatr Date: 2003-12 Impact factor: 4.406
Authors: Ricardo M Fernandes; Liza M Bialy; Ben Vandermeer; Lisa Tjosvold; Amy C Plint; Hema Patel; David W Johnson; Terry P Klassen; Lisa Hartling Journal: Cochrane Database Syst Rev Date: 2013-06-04
Authors: Francine M Ducharme; Gilles Chabot; Constantin Polychronakos; Francis Glorieux; Bruce Mazer Journal: Pediatrics Date: 2003-02 Impact factor: 7.124
Authors: Jocelyn R Grunwell; Samantha M Yeligar; Susan Stephenson; Xiao Du Ping; Theresa W Gauthier; Anne M Fitzpatrick; Lou Ann S Brown Journal: J Immunol Date: 2018-02-02 Impact factor: 5.422
Authors: Kawsari Abdullah; Deshayne B Fell; Dhenuka Radhakrishnan; Steven Hawken; David W Johnson; Piush Mandhane; Teresa To; Gary Joubert; Amy C Plint Journal: BMJ Open Date: 2021-05-03 Impact factor: 2.692
Authors: Jingyi Wang; Joseph Harold Walline; Lu Yin; Yili Dai; Jiayuan Dai; Huadong Zhu; Xuezhong Yu; Jun Xu Journal: Trials Date: 2021-01-06 Impact factor: 2.279